uniQure (NASDAQ:QURE) Coverage Initiated at Chardan Capital

Equities researchers at Chardan Capital initiated coverage on shares of uniQure (NASDAQ:QURE) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $38.00 price target on the biotechnology company’s stock. Chardan Capital’s price target points to a potential upside of 257.82% from the company’s current price.

QURE has been the topic of a number of other research reports. Stifel Nicolaus boosted their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. The Goldman Sachs Group boosted their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Mizuho increased their price target on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.80.

uniQure Price Performance

Shares of QURE opened at $10.62 on Tuesday. The firm has a market cap of $574.30 million, a PE ratio of -2.14 and a beta of 0.37. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The business’s 50 day moving average price is $13.50 and its two-hundred day moving average price is $10.89. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the transaction, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the transaction, the chief executive officer now owns 651,454 shares of the company’s stock, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is currently owned by insiders.

Institutional Trading of uniQure

Several hedge funds have recently made changes to their positions in QURE. RTW Investments LP purchased a new stake in uniQure in the 3rd quarter worth about $49,000. Quarry LP bought a new position in uniQure during the third quarter worth about $58,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of uniQure in the third quarter worth about $69,000. Twin Tree Management LP bought a new stake in shares of uniQure in the fourth quarter valued at approximately $77,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of uniQure in the fourth quarter valued at approximately $88,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.